The high-flying eye drug Eylea has hit some more turbulence in Germany. The country's cost-effectiveness watchdog said the Bayer drug doesn't perform any better than its Novartis ($NVS) rival, Lucentis, as a treatment for diabetic macular edema. The same group, the German Institute for Quality and Efficiency in Health Care (IQWiG), has said it was unable to assess the drug as a treatment for age-related macular degeneration because Bayer didn't provide enough relevant data. IQWiG's assessments are used by public insurers to determine how much to pay for drugs. Report